Central Jersey pharma, biotech news
The drug treats refractory mucocutaneous candidiasis infection. The Phase 2a study is being conducted at the National Institutes of Health Clinical Center in Bethesda, Md., under the direction of ... Preclinical data demonstrating MAT2501's oral ...
MyCentralJersey.com - Thu, 11 Feb 2016 19:22



Dry Mouth: More Common and Less Benign than Thought
... If left untreated, xerostomia can cause discomfort and contribute to halitosis, dental caries, periodontal disease, and other oral health problems, such as candidiasis infection due to disturbance of the oral microflora resulting from decreased ...
Pharmacy Times - Wed, 10 Feb 2016 15:48



Guest commentary: Emerging resistance, continuous progress in antifungal drug ...
In regards to the most common human mycosis, candidiasis, in recent years there has been a shift toward non-albicans Candida species with lower susceptibility to triazole drugs and the echinocandins. ... Two days before the mice were infected with ...
Healio - Thu, 11 Feb 2016 09:15

Matinas BioPharma Receives Notice of Allowance of U.S. Patent for Novel Lipid ...
The patent also includes pharmaceutical treatment of use claims for the Company's orally-administered lead anti-infective product candidates, MAT2203 (encochleated amphotericin B, a broad spectrum fungicidal medication) and MAT2501 (encochleated ...
CNNMoney - Wed, 10 Feb 2016 04:56

Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study ...
MAT2203 is Matinas BioPharma's orally-administered, encochleated formulation of the broad spectrum fungicidal medication amphotericin B. The Company's proprietary lipid-crystal nano-particle formulation of amphotericin B has a novel mechanism of ...
CNNMoney - Mon, 08 Feb 2016 04:00

Matinas BioPharma Commences Patient Enrollment in NIH-Sponsored Phase 2a Study ...
GlobeNewswire (press release) - Mon, 08 Feb 2016 04:00

Matinas BioPharma gets US patent for novel lipid-crystal nano-particle ...
The patent also includes pharmaceutical treatment of use claims for the company's orally-administered lead anti-infective product candidates, MAT2203 (encochleated amphotericin B, a broad spectrum fungicidal medication) and MAT2501 (encochleated ...
pharmabiz.com - Sat, 13 Feb 2016 00:26

Scynexis' (SCYX) SCY-078 Receives FDA Fast Track and QIDP Designations
The FDA granted QIDP and Fast Track designations for the oral formulation of SCY-078 for both the treatment of invasive candidiasis and invasive aspergillosis in 2014. The oral formulation is currently in Phase 2 development for both invasive ...
StreetInsider.com - Thu, 28 Jan 2016 06:03

SCYNEXIS Gets FDA Fast Track and QIDP Status For Fungal Infections Treatment ...
WallStreet.org - Thu, 28 Jan 2016 11:30



Fighting fungal infection: detecting signature compounds in breath
Candida albicans, naturally found in the human gut, is the most common cause of yeast infections in humans. It causes oral candidiasis, better known as thrush, which produces white patches on the tongue and a sore throat. Although Candida albicans is ...
separationsNOW.com - Sun, 31 Jan 2016 19:00


1  2  3  4  5  6  7  8    ->


We do not evaluate or guarantee the accuracy of any content in this site. Click here for the full disclaimer.

Last update: September 2014